# HUMANA INC (HUM)

Informational only - not investment advice.

CIK: 0000049071
SIC: 6324 Hospital & Medical Service Plans
SIC breadcrumb: [Finance, Insurance, And Real Estate](/division/H/) > [Insurance Carriers](/major-group/63/) > [SIC 6324 Hospital & Medical Service Plans](/industry/6324/)
Latest 10-K filed: 2026-02-19
SEC page: https://www.sec.gov/edgar/browse/?CIK=49071
Filing source: https://www.sec.gov/Archives/edgar/data/49071/000004907126000009/hum-20251231.htm

## At a glance

FY2025 · period end 2025-12-31 · filed 2026-02-19 · accession 0000049071-26-000009 · source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000049071.json

| Metric | Value | FY | Provenance |
| --- | ---: | ---: | --- |
| Revenue | 129,664,000,000 USD | 2025 | verified |
| Net income | 1,188,000,000 USD | 2025 | verified |
| Assets | 48,909,000,000 USD | 2025 | verified |
| Free cash flow | 375,000,000 USD | 2025 | computed |
| Net margin | 0.92% | 2025 | computed |
| Operating margin | 2.09% | 2025 | computed |
| Revenue YoY | +10.11% | 2025 | computed |
| ROE | 6.73% | 2025 | computed |

Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Net margin = net income ÷ revenue. Operating margin = operating income ÷ revenue. Revenue YoY = FY2025 revenue ÷ FY2024 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity.

Peer groups: [Managed care and health insurers](/compare/managed-care/) · SIC 6324 Hospital & Medical Service Plans

No market price, no rating, no forecast on this site. Not investment advice.

## Peer comparisons including HUM

- Managed care and health insurers: [peer review](/compare/managed-care/) · [market-risk page](/compare/managed-care/risk/)

### Peer percentile fingerprint

| Ratio | HUM | Peer median | Percentile | N |
| --- | ---: | ---: | ---: | ---: |
| Net margin | 0.9% | 1.0% | 44 | 10 |
| Operating margin | 2.1% | 1.3% | 67 | 10 |
| Revenue growth | 10.1% | 12.2% | 0 | 10 |
| FCF margin | 0.3% | 2.2% | 25 | 9 |
| ROE | 6.7% | 5.9% | 56 | 10 |
| ROA | 2.4% | 2.3% | 56 | 10 |
| Liabilities / equity | 1.77 | 2.43 | 33 | 10 |
| Current ratio | 2.00 | 1.50 | 100 | 10 |

Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC industry 6324 Hospital & Medical Service Plans, not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking.

## Selected Fundamentals
| Metric | Value | Unit | FY | Filed |
| --- | ---: | --- | ---: | --- |
| Revenue | 129664000000 | USD | 2025 | 2026-02-19 |
| Net income | 1188000000 | USD | 2025 | 2026-02-19 |
| Assets | 48909000000 | USD | 2025 | 2026-02-19 |

## Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-02-19. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000049071.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | 54,379,000,000 | 53,767,000,000 | 56,912,000,000 | 64,888,000,000 | 77,155,000,000 | 83,064,000,000 | 92,870,000,000 | 106,374,000,000 | 117,761,000,000 | 129,664,000,000 |
| Net income | 614,000,000 | 2,448,000,000 | 1,683,000,000 | 2,707,000,000 | 3,367,000,000 | 2,933,000,000 | 2,806,000,000 | 2,489,000,000 | 1,207,000,000 | 1,188,000,000 |
| Operating income | 1,741,000,000 | 4,262,000,000 | 3,100,000,000 | 3,192,000,000 | 4,986,000,000 | 3,148,000,000 | 3,800,000,000 | 4,013,000,000 | 2,562,000,000 | 2,704,000,000 |
| Diluted EPS | 4.07 | 16.81 | 12.16 | 20.10 | 25.31 | 22.67 | 22.08 | 20.00 | 9.98 | 9.84 |
| Operating cash flow | 1,936,000,000 | 4,051,000,000 | 2,173,000,000 | 5,284,000,000 | 5,639,000,000 | 2,262,000,000 | 4,587,000,000 | 3,981,000,000 | 2,966,000,000 | 921,000,000 |
| Capital expenditures | 527,000,000 | 524,000,000 | 612,000,000 | 736,000,000 | 964,000,000 | 1,342,000,000 | 1,137,000,000 | 1,004,000,000 | 575,000,000 | 546,000,000 |
| Dividends paid | 177,000,000 | 220,000,000 | 265,000,000 | 291,000,000 | 323,000,000 | 354,000,000 | 392,000,000 | 431,000,000 | 431,000,000 | 430,000,000 |
| Share buybacks | 104,000,000 | 3,365,000,000 | 1,090,000,000 | 1,070,000,000 | 1,820,000,000 | 79,000,000 | 2,096,000,000 | 1,573,000,000 | 817,000,000 | 151,000,000 |
| Assets | 25,396,000,000 | 27,178,000,000 | 25,413,000,000 | 29,074,000,000 | 34,969,000,000 | 44,358,000,000 | 43,055,000,000 | 47,065,000,000 | 46,479,000,000 | 48,909,000,000 |
| Liabilities | 14,711,000,000 | 17,336,000,000 | 15,252,000,000 | 17,037,000,000 | 21,241,000,000 | 28,255,000,000 | 27,685,000,000 | 30,747,000,000 | 30,034,000,000 | 31,172,000,000 |
| Stockholders' equity | 10,685,000,000 | 9,842,000,000 | 10,161,000,000 | 12,037,000,000 | 13,728,000,000 | 16,080,000,000 | 15,311,000,000 | 16,262,000,000 | 16,375,000,000 | 17,657,000,000 |
| Cash and cash equivalents | 3,877,000,000 | 4,042,000,000 | 2,343,000,000 | 4,054,000,000 | 4,673,000,000 | 3,394,000,000 | 5,061,000,000 | 4,694,000,000 | 2,221,000,000 | 4,200,000,000 |
| Free cash flow | 1,409,000,000 | 3,527,000,000 | 1,561,000,000 | 4,548,000,000 | 4,675,000,000 | 920,000,000 | 3,450,000,000 | 2,977,000,000 | 2,391,000,000 | 375,000,000 |

### Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net margin | 1.13% | 4.55% | 2.96% | 4.17% | 4.36% | 3.53% | 3.02% | 2.34% | 1.02% | 0.92% |
| Operating margin | 3.20% | 7.93% | 5.45% | 4.92% | 6.46% | 3.79% | 4.09% | 3.77% | 2.18% | 2.09% |
| Return on equity | 5.75% | 24.87% | 16.56% | 22.49% | 24.53% | 18.24% | 18.33% | 15.31% | 7.37% | 6.73% |
| Return on assets | 2.42% | 9.01% | 6.62% | 9.31% | 9.63% | 6.61% | 6.52% | 5.29% | 2.60% | 2.43% |
| Liabilities / equity | 1.38 | 1.76 | 1.50 | 1.42 | 1.55 | 1.76 | 1.81 | 1.89 | 1.83 | 1.77 |
| Current ratio | 2.07 | 1.85 | 1.68 | 1.82 | 1.77 | 1.62 | 1.52 | 1.59 | 1.76 | 2.00 |

## As-reported value updates

2 tracked differences above grepcent's stated thresholds were found between the earliest XBRL-filed value and the value currently on file for the same fiscal period.

Ledger: /company/HUM/revisions/


## Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-04-29. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0000049071.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

| Quarter | End date | Revenue | Net income | Diluted EPS | Method |
| --- | --- | ---: | ---: | ---: | --- |
| 2022-Q2 | 2022-06-30 |  |  | 5.48 | reported discrete quarter |
| 2022-Q3 | 2022-09-30 |  |  | 9.39 | reported discrete quarter |
| 2023-Q1 | 2023-03-31 |  |  | 9.87 | reported discrete quarter |
| 2023-Q2 | 2023-06-30 | 26,747,000,000 | 959,000,000 | 7.66 | reported discrete quarter |
| 2023-Q3 | 2023-09-30 | 26,423,000,000 | 832,000,000 | 6.71 | reported discrete quarter |
| 2023-Q4 | 2023-12-31 | 26,462,000,000 | -541,000,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2024-Q1 | 2024-03-31 | 29,611,000,000 | 741,000,000 | 6.11 | reported discrete quarter |
| 2024-Q2 | 2024-06-30 | 29,540,000,000 | 679,000,000 | 5.62 | reported discrete quarter |
| 2024-Q3 | 2024-09-30 | 29,397,000,000 | 480,000,000 | 3.98 | reported discrete quarter |
| 2024-Q4 | 2024-12-31 | 29,213,000,000 | -693,000,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2025-Q1 | 2025-03-31 | 32,112,000,000 | 1,244,000,000 | 10.30 | reported discrete quarter |
| 2025-Q2 | 2025-06-30 | 32,388,000,000 | 545,000,000 | 4.51 | reported discrete quarter |
| 2025-Q3 | 2025-09-30 | 32,649,000,000 | 195,000,000 | 1.62 | reported discrete quarter |
| 2025-Q4 | 2025-12-31 | 32,515,000,000 | -796,000,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2026-Q1 | 2026-03-31 | 39,648,000,000 | 1,186,000,000 | 9.83 | reported discrete quarter |

## Filed narrative (10-K & 10-Q)

## Business

Verbatim Item 1 Business section from HUM's latest 10-K: [/company/HUM/business/](/company/HUM/business/).

## Risk Factors

Verbatim Item 1A Risk Factors from HUM's latest 10-K: [/company/HUM/risk-factors/](/company/HUM/risk-factors/).

## Latest quarter (10-Q)

Latest 10-Q source: https://www.sec.gov/Archives/edgar/data/49071/000004907126000050/hum-20260630.htm

Extracted structurally from real Item 2 body heading to real Item 3/4 boundary.
Confidence: high
Filing date: 2026-07-29
Report date: 2026-06-30

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The condensed consolidated financial statements of Humana Inc. in this document present the Company’s financial position, results of operations and cash flows, and should be read in conjunction with the following discussion and analysis. References to “we,” “us,” “our,” “Company,” and “Humana” mean Humana Inc. and its subsidiaries. This discussion includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in filings with the Securities and Exchange Commission, or SEC, in our press releases, investor presentations, and in oral statements made by or with the approval of one of our executive officers, the words or phrases like “believes,” “expects,” “anticipates,” “intends,” “likely will result,” “estimates,” “projects” or variations of such words and similar expressions are intended to identify such forward–looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions, including, among other things, information set forth in Item 1A. – Risk Factors in our 2025 Form 10-K, as modified by any changes to those risk factors included in this document and in other reports we filed subsequent to February 19, 2026, in each case incorporated by reference herein. In making these statements, we are not undertaking to address or update such forward-looking statements in future filings or communications regarding our business or results. In light of these risks, uncertainties and assumptions, the forward–looking events discussed in this document might not occur. There may also be other risks that we are unable to predict at this time. Any of these risks and uncertainties may cause actual results to differ materially from the results discussed in the forward-looking statements.

Executive Overview

General

Humana Inc., headquartered in Louisville, Kentucky, is a leading U.S. healthcare company. Through our Humana insurance services and our CenterWell healthcare services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare and Medicaid, families, individuals, military service personnel, and communities at large.

Our industry relies on two key statistics to measure performance. The benefit ratio, which is computed by taking

total benefits expense as a percentage of premiums revenue, represents a statistic used to measure underwriting profitability. The operating cost ratio, which is computed by taking total operating costs, excluding depreciation and amortization, as a percentage of total revenues less investment income, represents a statistic used to measure administrative spending efficiency.

MaxHealth Acquisition

On February 13, 2026, we acquired MaxHealth, a leading primary care platform focused on providing high-quality, integrated care to adults and senior patients throughout Florida, for cash consideration of approximately $908 million, net of cash acquired. This resulted in a preliminary purchase price allocation to goodwill of approximately $800 million, other intangible assets of $71 million, and net tangible assets acquired of $59 million. The other intangible assets, which primarily consist of member relationships and trade names, have an estimated weighted average useful life of 6.9 years. The purchase price allocation is preliminary, subject to completion of valuation analysis, including for example, refining assumptions used to calculate the fair value of intangible assets.

Value Creation Initiatives and Impairment Charges

In order to create capacity to fund growth in our businesses, we committed to drive additional value for the enterprise through cost saving and productivity initiatives. In addition, in response to sustained macroeconomic, regulatory and competitive pressures impacting the industry, we initiated a substantial multi-year transformation program designed to re-align our cost structure, operating model and technology footprint with evolving market conditions.

As a result of these initiatives, we recorded charges of $56 million and $154 million for the three and six months ended June 30, 2026, respectively, and $29 million and $53 million for the three and six months ended June 30, 2025, respectively, within operating costs in the consolidated statements of income. The charges primarily relate

35

Table of Contents

to severance and associate exit costs, asset impairments, and external consulting expenses incurred to execute the program. We expect to incur additional charges over the course of the program.

In addition, we recorded impairment charges related to minority-interest investments of $21 million within net investment income in our condensed consolidated statements of income for the three and six months ended June 30, 2026 and $32 million, relating to indefinite-lived intangible assets, within operating costs in our condensed consolidated statements of income for the three and six months ended June 30, 2025.

Business Segments

Our two reportable segments, Insurance and CenterWell, are based on a combination of the type of health plan customer and adjacent businesses centered on well-being solutions for our health plans and other customers, as described below. Our Chief Executive Officer, the Chief Operating Decision Maker, utilizes these segment groupings and results of each segment, measured by income (loss) from operations, to assess performance and allocate resources primarily during our annual budget process and periodic forecast updates.

The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as our stand-alone prescription drug plans, or PDP, and contracts with various states to provide Medicaid, and Long-Term Support Services benefits, which we refer to collectively as our state-based contracts. This segment also includes products consisting of specialty health insurance benefits marketed to individuals and employer groups, including dental, vision, and other supplemental health benefits. In addition, our Insurance segment includes our Military services business as well as the operations of our PBM business.

The CenterWell segment includes our pharmacy solutions, primary care, and home solutions operations. Services offered by this segment are designed to enhance the overall healthcare experience. These services may lead to lower utilization associated with improved member health and/or lower drug costs.

Transactions between reportable segments primarily consist of sales of products and services rendered by our CenterWell segment, primarily pharmacy solutions, primary care, and home solutions, to our Insurance segment customers. Intersegment sales and expenses are recorded primarily at fair value and eliminated in consolidation. Members served by our segments often use the same provider networks, enabling us in some instances to obtain more favorable contract terms with providers. Our segments also share indirect costs and assets. As a result, the profitability of each segment is interdependent. We allocate most operating expenses to our segments. Assets and certain corporate income and expenses are not allocated to the segments, including the portion of investment income not supporting segment operations, interest expense on corporate debt, and certain other corporate expenses. These items are managed at a corporate level. These corporate amounts are reported separately from our reportable segments and are included with intersegment eliminations.

Seasonality

Our Medicare benefit costs rise as members pay their contractual portion of claims responsibility, progress through their annual deductible and maximum out-of-pocket expenses, as well as incurring higher episodic cost of care resulting in a higher benefit ratio throughout the year.

Our quarterly Insurance segment earnings and operating cash flows are impacted by the Medicare Part D benefit design and changes in the composition of our stand-alone PDP membership. The Medicare Part D benefit design results in coverage that varies as a member’s cumulative out-of-pocket costs pass through successive stages of a member’s plan period, which begins annually on January 1 for renewals. The benefit design changes associated with the implementation of the Inflation Reduction Act of 2022, or IRA, reduced out-of-pocket costs for beneficiaries, resulting in greater cost sharing and a leveling of net prescription costs throughout the year. In addition, the number of low income senior members as well as year-over-year changes in the mix of membership in our stand-alone PDP products affects the quarterly benefit ratio pattern.

The Insurance segment also experiences seasonality in the operating cost ratio as a result of costs incurred in the

second half of the year associated with the Medicare marketing season.

36

Table of Contents

2026 Highlights

•Our strategy is to offer our members affordable health care combined with a positive consumer experience in growing markets. At the core of this strategy is our integrated care delivery model, which unites quality care, high member engagement, and sophisticated data analytics. Our approach to primary, physician-directed care for our members aims to provide quality care that is consistent, integrated, cost-effective, and member-focused, provided by both employed physicians and physicians with network contract arrangements. The model is designed to improve health outcomes and affordability for individuals and for the health system as a whole, while offering our members a simple, seamless healthcare experience. We believe this strategy is positioning us for long-term growth in both membership and earnings. We offer providers a continuum of opportunities to increase the integration of care and offer assistance to providers in transitioning from a fee-for-service to a value-based arrangement. These include performance bonuses, shared savings and shared risk relationships. At June 30, 2026, approximately 4,118,700 members, or 64%, of our individual Medicare Advantage members were in value-based relationships under our integrated care delivery model, as compared to 3,542,300 members, or 68%, at June 30, 2025.

•Net income attributable to Humana was $694 million, or $5.73 per diluted common share, and $545 million, or $4.51 per diluted common share, for the three months ended June 30, 2026 and 2025, respectively. Net income attributable to Humana was $1.9 billion, or $15.55 per diluted common share, and $1.8 billion, or $14.81 per diluted common share, for the six months ended June 30, 2026 and 2025, respectively. These comparisons were impacted by put/call valuation adjustments associated with non-consolidating minority interest investments, impairment charges and charges associated with value creation initiatives. The impact of these adjustments to our consolidated income before income taxes and equity in net losses and diluted earnings per common share was as follows for the 2026 and 2025 quarter and period:

[Excerpt truncated for page length; source filing is linked above.]

## Latest 10-K MD&A (excerpt)

Latest 10-K Item 7 source: https://www.sec.gov/Archives/edgar/data/49071/000004907126000009/hum-20251231.htm
Complete FY 2025 MD&A: /company/HUM/mda/fy2025/

Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary. Published MD&A gate trimmed front/tail over-capture.
Confidence: high
Filing date: 2026-02-19
Report date: 2025-12-31

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

For discussion of 2023 items and year-over-year comparisons between 2024 and 2023 that are not included in this 2025 Form 10-K, refer to "Item 7. – Management Discussion and Analysis of Financial Condition and Results of Operations" found in our Form 10-K for the year ended December 31, 2024, that was filed with the Securities and Exchange Commission on February 20, 2025.

Executive Overview

General

Humana Inc., headquartered in Louisville, Kentucky, is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for Medicare and Medicaid participants, families, individuals, military service personnel, and communities at large.

Our industry relies on two key statistics to measure performance. The benefit ratio, which is computed by taking total benefits expense as a percentage of premiums revenue, represents a statistic used to measure underwriting profitability. The operating cost ratio, which is computed by taking total operating costs, excluding depreciation and amortization, as a percentage of total revenue less investment income, represents a statistic used to measure administrative spending efficiency.

Employer Group Commercial Medical Products Business Exit

During 2025, we finalized our exit from the Employer Group Commercial Medical Products business, which included all fully insured, self-funded and Federal Employee Health Benefit medical plans, as well as associated wellness and rewards programs. No other Humana health plan offerings were materially affected. Following a strategic review, we determined the Employer Group Commercial Medical Products business was no longer positioned to sustainably meet the needs of commercial members over the long term or support our long-term strategic plans.

Value Creation Initiatives and Impairment Charges

In order to create capacity to fund growth in our businesses, we committed to drive additional value for the enterprise through cost saving and productivity initiatives. In addition, in response to sustained macroeconomic, regulatory and competitive pressures impacting the industry, we initiated a substantial multi-year transformation program designed to re-align our cost structure, operating model and technology footprint with evolving market conditions.

As a result of these initiatives, we recorded charges of $449 million, $281 million and $436 million in 2025, 2024 and 2023, respectively, primarily within operating costs in the consolidated statements of income. We expect to incur additional charges over the course of the program.

The value creation initiative charges primarily relate to $329 million, $25 million and $199 million in severance and other employee related charges in connection with workforce optimization in 2025, 2024 and 2023, respectively, as well as $40 million, $256 million and $237 million in asset impairments in 2025, 2024 and 2023, respectively. The remainder of the 2025 charges primarily relate to external consulting spend.

In addition, we recorded impairment charges of $253 million, $200 million and $91 million in 2025, 2024 and 2023, respectively. The impairment charges included impairment of indefinite-lived intangible assets for $128 million, $200 million and $55 million in 2025, 2024 and 2023, respectively, included within operating costs in our consolidated statements of income. The remaining impairment charges were included within investment income in our consolidated statements of income.

41

In addition to the value creation initiatives, we also recorded severance charges of $70 million in 2023 within operating costs in our consolidated statement of income as a result of our exit from the Employer Group Commercial Medical Products business.

Business Segments

Our two reportable segments, Insurance and CenterWell, are based on a combination of the type of health plan customer and adjacent businesses centered on well-being solutions for our health plans and other customers, as described below. Our Chief Executive Officer, the Chief Operating Decision Maker, utilizes these segment groupings and results of each segment, measured by income (loss) from operations, to assess performance and allocate resources primarily during our annual budget process and periodic forecast updates. For segment financial information, refer to Note 18 to the audited Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Form 10-K.

The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as our contract with CMS to administer the Limited Income Newly Eligible Transition, or LI-NET, prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits, which we refer to collectively as our state-based contracts. This segment also includes products consisting of specialty health insurance benefits marketed to individuals and employer groups, including dental, vision, and other supplemental health benefits. In addition, our Insurance segment includes our Military services business, primarily our T-5 East Region contract, as well as the operations of our PBM business.

The CenterWell segment includes our pharmacy solutions, primary care, and home solutions operations. Services offered by this segment are designed to enhance the overall healthcare experience. These services may lead to lower utilization associated with improved member health and/or lower drug costs.

Transactions between reportable segments primarily consist of sales of products and services rendered by our CenterWell segment, primarily pharmacy solutions, primary care, and home solutions, to our Insurance segment customers. Intersegment sales and expenses are recorded primarily at fair value and eliminated in consolidation. Members served by our segments often use the same provider networks, enabling us in some instances to obtain more favorable contract terms with providers. Our segments also share indirect costs and assets. As a result, the profitability of each segment is interdependent. We allocate most operating expenses to our segments. Assets and certain corporate income and expenses are not allocated to the segments, including the portion of investment income not supporting segment operations, interest expense on corporate debt, and certain other corporate expenses. These items are managed at a corporate level. These corporate amounts are reported separately from our reportable segments and are included with intersegment eliminations.

Seasonality

Our Medicare benefit costs rise as members pay their contractual portion of claims responsibility, progress through their annual deductible and maximum out-of-pocket expenses, as well as incurring higher episodic cost of care resulting in a higher benefit ratio throughout the year.

Our quarterly Insurance segment earnings and operating cash flows are impacted by the Medicare Part D benefit design and changes in the composition of our stand-alone prescription drug plan, or PDP, membership. The Medicare Part D benefit design results in coverage that varies as a member’s cumulative out-of-pocket costs pass through successive stages of a member’s plan period, which begins annually on January 1 for renewals. Effective January 1, 2025, the Medicare Part D coverage gap was eliminated as mandated by the Inflation Reduction Act of 2022, or IRA. The benefit design changes reduced out-of-pocket costs for beneficiaries, resulting in greater cost sharing and a leveling of net prescription costs throughout the year as compared to the historical seasonal decline prior to the IRA. In addition, the number of low income senior members as well as year-over-year changes in the mix of membership in our stand-alone PDP products affects the quarterly benefit ratio pattern.

42

The Insurance segment also experiences seasonality in the operating cost ratio as a result of costs incurred in the second half of the year associated with the Medicare marketing season.

Highlights

•Our strategy is to offer our members affordable health care combined with a positive consumer experience in growing markets. At the core of this strategy is our integrated care delivery model, which unites quality care, high member engagement, and sophisticated data analytics. Our approach to primary, physician-directed care for our members aims to provide quality care that is consistent, integrated, cost-effective, and member-focused, provided by both employed physicians and physicians with network contract arrangements. The model is designed to improve health outcomes and affordability for individuals and for the health system as a whole, while offering our members a simple, seamless healthcare experience. We believe this strategy is positioning us for long-term growth in both membership and earnings. We offer providers a continuum of opportunities to increase the integration of care and offer assistance to providers in transitioning from a fee-for-service to a value-based arrangement. These include performance bonuses, shared savings and shared risk relationships. At December 31, 2025, approximately 3,586,100 members, or 68%, of our individual Medicare Advantage members were in value-based relationships under our integrated care delivery model, as compared to 3,994,300 members, or 71%, at December 31, 2024.

•Net income attributable to Humana was $1.2 billion, or $9.84 per diluted common share, and $1.2 billion, or $9.98 per diluted common share, in 2025 and 2024, respectively. This comparison was significantly impacted by put/call valuation adjustments associated with non-consolidating minority interest investments, charges associated with value creation initiatives, impairment charges, loss on sale of business and settlement of certain litigation expenses. The impact of these adjustments to our consolidated income before income taxes and equity in net earnings and diluted earnings per common share was as follows for the 2025 and 2024 periods:

[[GREPCENT_TABLE]]
[["","2025","","2024"],["","(in millions)"],["Consolidated income before income taxes and equity in net losses:"],["Put/call valuation adjustments associated with our non-consolidating minority interest investments","$","513","","","$","296"],["Value creation initiatives","449","","","281"],["Impairment charges","253","","","200"],["Loss on sale of business","67","","","\u2014"],["Settlement of certain litigation expenses","15","","","\u2014"],["Total","$","1,297","","","$","777"],["","2025","","2024"],["Diluted earnings per common share:"],["Put/call valuation adjustments associated with our non-consolidating minority interest investments","$","4.25","","","$","2.45"],["Value creation initiatives","3.72","","","2.33"],["Impairment charges","2.09","","","1.65"],["Loss on sale of business","0.55","","","\u2014"],["Settlement of certain litigation expenses","0.13","","","\u2014"],["Cumulative net tax impact","(3.36)","","","(1.50)"],["Total","$","7.38","","","$","4.93"]]
[[/GREPCENT_TABLE]]

43

Regulatory Environment

We are and will continue to be regularly subject to new laws and regulations, changes to existing laws and regulations, and judicial determinations that impact the interpretation and applicability of those laws and regulations. The Health Care Reform Law, the Families First Act, the CARES Act, and the Inflation Reduction Act, and related regulations, are examples of laws which have enacted significant reforms to various aspects of the U.S. health insurance i

[Excerpt truncated for page length; the complete text is on the linked full-MD&A page.]

Read the full FY 2025 MD&A: /company/HUM/mda/fy2025/
All MD&A years: /company/HUM/mda/


## MD&A history

Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page.

- [FY 2024 MD&A](/company/HUM/mda/fy2024/): filed 2025-02-20; accession 0000049071-25-000007 (https://www.sec.gov/Archives/edgar/data/49071/000004907125000007/hum-20241231.htm)
- [FY 2023 MD&A](/company/HUM/mda/fy2023/): filed 2024-02-15; accession 0000049071-24-000012 (https://www.sec.gov/Archives/edgar/data/49071/000004907124000012/hum-20231231.htm)
- [FY 2022 MD&A](/company/HUM/mda/fy2022/): filed 2023-02-16; accession 0000049071-23-000011 (https://www.sec.gov/Archives/edgar/data/49071/000004907123000011/hum-20221231.htm)
- [FY 2021 MD&A](/company/HUM/mda/fy2021/): filed 2022-02-17; accession 0000049071-22-000017 (https://www.sec.gov/Archives/edgar/data/49071/000004907122000017/hum-20211231.htm)




## Macro cross-references

Indicators mapped to this company's SIC classification (industry 6324 Hospital & Medical Service Plans) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim.

- [FEDFUNDS](/indicator/FEDFUNDS/): Federal Funds Effective Rate
- [DGS10](/indicator/DGS10/): Market Yield on U.S. Treasury Securities at 10-Year Constant Maturity
- [PCEPI](/indicator/PCEPI/): Personal Consumption Expenditures: Chain-type Price Index

Macro-to-micro threads including this sector: [Money & trade](/thread/money-trade/), [Government finances](/thread/government-finances/), [Sector employment](/thread/sector-employment/).

All macro indicators: /indicators/


## For LLMs & downloads

Markdown twin: /company/HUM.md · JSON record: /company/HUM.json · verified financials: /company/HUM/financials.json / /company/HUM/financials.csv · machine TOC for the whole site: /llms.txt